Compare Adaptive Biotechnologies Corp (ADPT) vs EPR Properties (EPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs EPR Properties — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while EPR Properties trades at $59.63 (market cap $4.58B). The key difference: EPR Properties is the larger of the two by market cap, and EPR Properties pays a 6.22% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | EPR | |
|---|---|---|
Market Cap | $3.33B | $4.58B |
Sector | Health | Real Estate |
52-Week High | $22.37 | $61.21 |
52-Week Low | $10.24 | $48.71 |
Enterprise Value | $3.19B | $7.64B |
Dividend Yield | — | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
EPR Properties trades at $59.21, up 0.19% today, with a bullish technical signal supported by moving averages. The REIT shows strong profitability with a 39.93% net income margin and consistent earnings beats, including Q1 2026 EPS of $1.26 versus $0.76 expected. Recent news highlights a $315 million Six Flags acquisition and inclusion on J.P. Morgan's July Focus List (247 Wallst, 2026-07-07).
Outlook remains positive with a consensus price target of $63.00, offering 6.4% upside. Key risks include reliance on experiential assets like theaters amid economic sensitivity, while the 6.2% dividend yield provides income support. Earnings on July 29, 2026, will be critical for validating growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
